At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 14 enrolled
Drug / intervention
Docetaxel +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Phase I of Oral Nintedanib Plus Weekly Docetaxel Therapy in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma After Failure of Platinum -Based First Line Chemotherapy
In Brief
A Phase 1 clinical trial evaluating Docetaxel and Nintedanib for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 14 participants across 4 sites in 2 countries.
Detailed Summary
Phase I study. To determine the MTD (Maximum Tolerated Dose) of nintedanib + weekly Docetaxel in patients with locally advanced or metastatic lung adenocarcinoma after failure of platinum-based first line chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesFrance, Germany
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartMar 2016
Primary CompletionNov 2019
TodayJul 2026
First PostedJan 29, 2016
Enrollment StartMar 7, 2016
Primary CompletionNov 27, 2019
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 10.4 years ago
Interventions
Docetaxeldrug
Nintedanibdrug
Low Dose
Nintedanibdrug
Medium dose
Nintedanibdrug
High dose
Nintedanibdrug
Continuous high dose